EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma

Wenxin Shen iD, Qianlan Zhou, Qinzhen Zhang, Lina Han, Li Chen, Xiaowen Li, Bing Dai, Si Liu, Lishen Shan

International Forum of Allergy & Rhinology · 2025-02 · 15 (2) · 208-211

DOI: 10.1002/alr.23470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 15.10.2024. Verfasst von Wenxin Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics Respiration, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Omalizumab, Asthma, Desensitization, Immunologic, Anti-Asthmatic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Scientific Research Fund of Liaoning Provincial Education Department, Basic Scientific Research Project of Colleges and Universities of Liaoning Province (Key Program).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key points Omalizumab enables children who are intolerant to AIT to initiate AIT successfully. Combination therapy better improves asthma and rhinitis symptoms, FeNO, and lung function compared to single SCIT or omalizumab treatment. Combination therapy reduces the incidence of adverse reactions during the initial phase of SCIT and enhances its safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabAsthmaDesensitization, ImmunologicAnti-Asthmatic AgentsHumansChildTreatment OutcomeFemaleMaleAdolescentAllergensCombined Modality Therapy

Stichwörter der Autor:innen

allergen immunotherapycombination therapyefficacymoderate to severe allergic asthma in childrenomalizumabsafety

Substanzen

OmalizumabAnti-Asthmatic AgentsAllergens

Autor:innen und Institutionen

  • Department of Pediatrics Respiration, Shengjing Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Wenxin Shen

Förderung

  • Scientific Research Fund of Liaoning Provincial Education Department
  • Basic Scientific Research Project of Colleges and Universities of Liaoning Province (Key Program)

Zitieren

APA

Shen, W., Zhou, Q., Zhang, Q., Han, L., Chen, L., Li, X., Dai, B., Liu, S., & Shan, L. (2025). Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma. International Forum of Allergy & Rhinology, 15(2), 208-211. https://doi.org/10.1002/alr.23470

Vancouver

Shen W, Zhou Q, Zhang Q, Han L, Chen L, Li X, et al. Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma. International Forum of Allergy & Rhinology. 2025;15(2):208-211. doi:10.1002/alr.23470

BibTeX
@article{Shen2025,
  author = {Shen, Wenxin and Zhou, Qianlan and Zhang, Qinzhen and Han, Lina and Chen, Li and Li, Xiaowen and Dai, Bing and Liu, Si and Shan, Lishen},
  title = {Efficacy and safety of omalizumab combined with allergen immunotherapy in children with moderate to severe allergic asthma},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {208--211},
  doi = {10.1002/alr.23470}
}
Kostenlos starten →